Effect of imatinib on growth of experimental endometriosis in rats

Yildiz C, Caglar Yildiz, Kacan T, Turgut Kacan, Akkar OB, Ozlem Bozoklu Akkar, Savas Karakus, Karakus S, Metin Seker, Seker M, Kacan SB, Selen Baloglu Kacan, Ozer H, Hatice Ozer, Ali Çetin, Ali Cetin
European journal of obstetrics, gynecology, and reproductive biology · 2016 · doi:10.1016/j.ejogrb.2015.12.013 · PMID:26773307
other OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Imatinib, along with anastrozole, suppressed experimental endometriosis growth in rats by reducing endometriotic tissue and ovarian follicles, likely through inhibition of angiogenesis and cell proliferation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Currently, medical and surgical treatment options for endometriosis are limited due to suboptimal efficacy, and also safety and tolerance issues. Long-term use of gonadotrophin-releasing hormone analogs, androgenes, and the danazol, which are widely used drugs for endometriosis, is usually not possible due to their suboptimal safety and tolerance profile. The lack of an effective, tolerable and safe treatment option for endometriosis makes animal models of experimental endometriosis necessary to study candidate drugs. The aim of this study was to investigate the efficacy of imatinib on the experimental endometriosis in a rat model. STUDY DESIGN: Endometriosis was induced by autotransplantation of uterine tissue into the peritoneal cavity. Twenty-four rats, which had visually confirmed endometriotic implants on subsequent laparotomy, were randomized into three groups to receive imatinib (25mg/kg/day, p.o.), anastrozole (0.004 mg/day, p.o.), or normal saline (0.1 mL, i.p.) for 14 days. After removal of endometriotic tissue and H & E staining, endometriosis score was determined according to a semiquantitative histological classification. Also, immunostaining with primary antibodies including VEGF, CD117, and Bax were used for immunohistochemical (IHC) examination. RESULTS: Both anastrozole and imatinib suppressed the growth of endometriotic tissue and reduced the number of ovarian follicles. Although the difference was not statistically significant, imatinib was less effective than anastrozole for treatment of endometriosis. CONCLUSION: Imatinib effectively treats experimental endometriosis by its inhibitor effects on angiogenesis and cell proliferation.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Aromatase Inhibitors Cell Proliferation Endometriosis Endometriosis Endometrium Imatinib Mesylate Nitriles Peritoneal Diseases Peritoneal Diseases Peritoneum Triazoles Anastrozole Angiogenesis Inhibitors Animals Aromatase Inhibitors bcl-2-Associated X Protein bcl-2-Associated X Protein bcl-2-Associated X Protein Cell Proliferation

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (40)

SciLite annotations

chemicals 9
imatinib androgen danazol imatinib imatinib anastrozole anastrozole imatinib anastrozole
organisms 4
rattus sp. rodents zitter rats rattus sp.

Source provenance

crossref
last seen: 2026-06-20T06:34:59.460456+00:00
europepmc
last seen: 2026-09-17T06:16:55.786923+00:00
pubmed
last seen: 2026-05-13T22:21:19.813018+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine